COSTEM 2019 | Tisagenlecleucel for R/R DLBCL

Stephen Schuster

Stephen Schuster, MD, University of Pennsylvania, Philadelphia, PA, talks on his study regarding tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients without measurable disease at infusion, outlining the main methods, aims and findings of the trial. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video